
Gefticip 250mg tablet
Salt Composition: Gefitinib
Expiry Date: 01/2028
Inclusive of all taxes
30 tablet
About The Product
Lung Cancer
Gefticip 250mg tablet is a chemotherapy medication that is used in the treatment of non-small cell lung cancer (NSCLC). The generic name of this medication is Gefitinib. It is a tyrosine kinase inhibitor that shows antineoplastic activity. Gefticip is used in the first-line treatment of lung cancer that has genetic mutations.
Side Effects
- Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects.
- In that case, the patient should contact the doctor immediately.
- Some common side effects of Entekor 1mg Tablet include: Mouth sores Dry skin Loss of appetite Blisters of skin Vomiting Hives on the skin Shortness of breath Dark coloration of urine Yellowing of skin and eyes Nausea Sensitivity to light Vision complications Acne Extreme weakness Diarrhea Seek medical attention in case of any unusual or severe side effects immediately.
How To Use
- The dosage and treatment duration of the Gefticip 250mg tablet are decided by the doctor according to the stage of cancer and the overall patient's health.
- This tablet should be taken with or without food, but at the fix time every day to get effective results.
- Don't miss a dose or overdose on the medicine.
Safety Advice
Missed Doses
- It is advisable to avoid missing any doses of Gefticip and in case you miss a dose of Gefticip consult your doctor immediately.
-
FAQs
Gefticip 250mg tablet is an anticancer medication that is primarily used in the treatment of lung cancer.
Reference
1. Uhm, J.
H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J.
C., Buckner, J. C., ... & Jaeckle, K.
A. (2011).
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology* Biology* Physics, 80(2), 347-353.
2. Herbst, R.
S., Fukuoka, M., & Baselga, J. (2004).
Gefitinib—a novel targeted approach to treating cancer. Nature Reviews Cancer, 4(12), 956-965.
3. Rawluk, J., & Waller, C.
F. (2018).
Gefitinib. Small molecules in oncology, 235-246.
4. Giaccone, G.
(2004). The role of gefitinib in lung cancer treatment.
Clinical cancer research, 10(12), 4233s-4237s. 5.
Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H.
(2004). Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Journal of hepatology, 41(6), 1008-1016. 6.
Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., ... & Yamamoto, K. (2012).
Review of the treatment of non-small cell lung cancer with gefitinib. Clinical Medicine Insights: Oncology, 6, CMO-S7340.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
